These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11709513)

  • 1. A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease.
    Leiper K; Woolner J; Mullan MM; Parker T; van der Vliet M; Fear S; Rhodes JM; Hunter JO
    Gut; 2001 Dec; 49(6):790-4. PubMed ID: 11709513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial.
    Verma S; Brown S; Kirkwood B; Giaffer MH
    Am J Gastroenterol; 2000 Mar; 95(3):735-9. PubMed ID: 10710067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enteral feeding as sole treatment for Crohn's disease: controlled trial of whole protein v amino acid based feed and a case study of dietary challenge.
    Raouf AH; Hildrey V; Daniel J; Walker RJ; Krasner N; Elias E; Rhodes JM
    Gut; 1991 Jun; 32(6):702-7. PubMed ID: 1905672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-chain triglycerides reduce the efficacy of enteral feeds in patients with active Crohn's disease.
    Middleton SJ; Rucker JT; Kirby GA; Riordan AM; Hunter JO
    Clin Nutr; 1995 Aug; 14(4):229-36. PubMed ID: 16843936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term efficacy of enteral nutrition in the treatment of active Crohn's disease: a randomized, controlled trial comparing nutrient formulas.
    Sakurai T; Matsui T; Yao T; Takagi Y; Hirai F; Aoyagi K; Okada M
    JPEN J Parenter Enteral Nutr; 2002; 26(2):98-103. PubMed ID: 11871742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group).
    Lorenz-Meyer H; Bauer P; Nicolay C; Schulz B; Purrmann J; Fleig WE; Scheurlen C; Koop I; Pudel V; Carr L
    Scand J Gastroenterol; 1996 Aug; 31(8):778-85. PubMed ID: 8858747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial.
    Gassull MA; Fernández-Bañares F; Cabré E; Papo M; Giaffer MH; Sánchez-Lombraña JL; Richart C; Malchow H; González-Huix F; Esteve M;
    Gut; 2002 Aug; 51(2):164-8. PubMed ID: 12117873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose naltrexone for induction of remission in Crohn's disease.
    Segal D; Macdonald JK; Chande N
    Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
    Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
    J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enteral nutritional therapy for inducing remission of Crohn's disease.
    Zachos M; Tondeur M; Griffiths AM
    Cochrane Database Syst Rev; 2001; (3):CD000542. PubMed ID: 11686966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budesonide for induction of remission in Crohn's disease.
    Rezaie A; Kuenzig ME; Benchimol EI; Griffiths AM; Otley AR; Steinhart AH; Kaplan GG; Seow CH
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD000296. PubMed ID: 26039678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
    Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ
    Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet Activation Markers Are Associated with Crohn's Disease Activity in Patients with Low C-Reactive Protein.
    Takeyama H; Mizushima T; Iijima H; Shinichiro S; Uemura M; Nishimura J; Hata T; Takemasa I; Yamamoto H; Doki Y; Mori M
    Dig Dis Sci; 2015 Nov; 60(11):3418-23. PubMed ID: 26077975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
    Sandborn WJ; Colombel JF; D'Haens G; Plevy SE; Panés J; Robinson AM; Pollack PF; Zhou Q; Castillo M; Thakkar RB
    Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitrogen sparing effect of structured triglycerides containing both medium-and long-chain fatty acids in critically ill patients; a double blind randomized controlled trial.
    Lindgren BF; Ruokonen E; Magnusson-Borg K; Takala J
    Clin Nutr; 2001 Feb; 20(1):43-8. PubMed ID: 11161543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.
    Dignass A; Stoynov S; Dorofeyev AE; Grigorieva GA; Tomsová E; Altorjay I; Tuculanu D; Bunganič I; Pokrotnieks J; Kupčinskas L; Dilger K; Greinwald R; Mueller R;
    J Crohns Colitis; 2014 Sep; 8(9):970-80. PubMed ID: 24534142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Petryka R; Kuehbacher T; Hebuterne X; Roblin X; Klopocka M; Goldis A; Wisniewska-Jarosinska M; Baranovsky A; Sike R; Stoyanova K; Tasset C; Van der Aa A; Harrison P
    Lancet; 2017 Jan; 389(10066):266-275. PubMed ID: 27988142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study.
    Eser A; Colombel JF; Rutgeerts P; Vermeire S; Vogelsang H; Braddock M; Persson T; Reinisch W
    Inflamm Bowel Dis; 2015 Oct; 21(10):2247-53. PubMed ID: 26197451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
    Sandborn WJ; Feagan BG; Radford-Smith G; Kovacs A; Enns R; Innes A; Patel J
    Gut; 2004 Oct; 53(10):1485-93. PubMed ID: 15361500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.